Published in Women's Health Weekly, October 26th, 2006
Pevion Biotech, in collaboration with Bio Life Science (Vienna), has designed a therapeutic peptide vaccine to protect breast cancer patients from tumor recurrence following treatment of the primary tumor. The vaccine uses synthetic peptide antigens originating from the HER-2/neu oncoprotein, a protein almost exclusively present on cancerous cells, specifically breast cancer cells.
The antigens were identified by Bio...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly